Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | SRNE |
---|---|---|
09:32 ET | 2980 | 0.0045 |
09:34 ET | 54150 | 0.005 |
10:19 ET | 2300 | 0.0042 |
10:33 ET | 27000 | 0.0035 |
11:15 ET | 100 | 0.0036 |
11:24 ET | 100 | 0.0036 |
11:33 ET | 10000 | 0.0036 |
11:36 ET | 7950 | 0.0036 |
11:44 ET | 260 | 0.0036 |
12:36 ET | 132 | 0.0027 |
12:41 ET | 500 | 0.0037 |
01:01 ET | 4600 | 0.0027 |
01:33 ET | 250 | 0.0027 |
01:46 ET | 7800 | 0.0027 |
02:08 ET | 2000 | 0.0037 |
02:09 ET | 1600 | 0.0027 |
02:49 ET | 300 | 0.0017 |
03:39 ET | 13263 | 0.005 |
03:52 ET | 501 | 0.0027 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Sorrento Therapeutics Inc | 2.8M | 0.0x | --- |
Centogene NV | 5.0M | -0.1x | --- |
MEI Pharma Inc | 19.3M | 1.1x | --- |
Molecular Templates Inc | 9.0M | -0.5x | --- |
Bioqual Inc | 60.4M | 63.1x | -25.28% |
Neptune Wellness Solutions Inc | 86.1K | 0.0x | --- |
Sorrento Therapeutics, Inc. is a clinical and commercial stage biopharmaceutical company. The Company is engaged in developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune diseases and COVID-19. The Company’s segments include Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around its Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate the next-generation of cancer therapeutics. The Scilex segment is organized around its non-opioid pain management operations and clinical pipeline. The Company’s immuno-oncology platforms, including its fully human antibodies (G-MAB library), ACEA small molecule library, immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs) and oncolytic virus (Seprehvec). The Company is also developing potential antiviral therapies against COVID-19, including FUJOVEE (Abivertinib) and its rapid diagnostic test, including COVIMARK.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.8M |
---|---|
Revenue (TTM) | $64.3M |
Shares Outstanding | 551.3M |
Sorrento Therapeutics Inc does not pay a dividend. | |
Beta | 1.80 |
EPS | $-1.09 |
Book Value | $-0.04 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 0.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -734.68% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.